Jefferson Physician Warns Further Study Of DHEA's Safety Needed

September 10, 1998

An endocrinologist at Jefferson Medical College cautions that a natural hormone and popular food supplement believed by many to have anti-aging properties may actually increase men's risk of prostate cancer. Marshall Goldberg, M.D., professor of medicine and psychiatry at Jefferson Medical College of Thomas Jefferson University in Philadelphia, says that dehydroepiandrosterone (DHEA) may stimulate the production of other hormones in the body, resulting in increased levels of insulin-like growth factor-1 (IGF-1). IGF-1 can cause abnormal growth of prostate cells.

DHEA is a popular item sold in health food stores for its purported protective properties against such age-related diseases as cancer, heart disease, Alzheimer's disease and diabetes. Blood levels of DHEA, the most abundant hormone in the body, rise after puberty, peak between the ages 25-30, then decline throughout the rest of life by as much as 80 percent from its peak.

Earlier this year, researchers reported in Science, a four- to seven-fold increase in the risk of developing prostate cancer, particularly those over 60, whose blood levels of IGF-1 were higher than normal. And Dr. Goldberg reports supplements of DHEA, even as small as 25 milligrams a day, significantly raise IGF-1 levels.

Writing in the August issue of the journal Emergency Medicine, Dr. Goldberg suggests that if the link among high blood levels of DHEA, IGF-1, and the risk of prostate cancer can be confirmed, "regulation of DHEA makes sense.

"This is a real risk factor for prostate cancer," he says. He worries that the unregulated and medically-unsupervised use of this hormone may eventually prove dangerous to some people, while its beneficial effects are at best unproved. Many people over 50 take DHEA, thinking that a little won't hurt, and it could possibly help to improve their sense of well-being. He estimates that more than 1 million people in this country are currently taking DHEA supplements.

Dr. Goldberg also worries about potential hormone abuse among adolescents, particularly in light of St. Louis Cardinal slugger Mark McGwire's recent admission of using androstenedione, a steroid hormone related to DHEA, to bolster his hitting power. The recent controversy over this steroid's properties, and its possible connection to McGwire's success, may move some teenagers from contemplating to actually taking such over-the-counter drugs in the unproved belief that it will enhance their strength.

DHEA can produce unpleasant side-effects in women as well. A 1994 study showed that blood testosterone measurements rose in most females given DHEA, and in some cases, doubled their male hormone levels. This, in turn, can result in acne, unsightly facial hair, irregular menstruation and loss of scalp hair. Dr. Goldberg strongly recommends that men taking DHEA supplements have their serum DHEA, PSA (prostate-specific antigen, a marker in the blood indicating the possible presence of prostate cancer) and IGF-1 levels checked periodically. Women taking DHEA should have their testosterone levels monitored.

"Whether or not DHEA proves to slow the aging process, as it may well do," he writes, "it is not without its potential dangers." Much more needs to be learned about the actions, applications and misapplications of this powerful and all too easily available hormone.Dr. Goldberg also cautions that like any drug, there may be drug-drug interactions. He is, however, encouraged that much more research is being done on DHEA. "Now, the National Institutes of Health are conducting studies on it," he reports in his article.


Thomas Jefferson University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to